Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454518 | 1.00 | TLR7 (1.00) | TLR7 | |
| SCHEMBL29454517 | 1.00 | TLR7 (1.00) | TLR7 | |
| SCHEMBL1876573 | 0.90 | TLR7 (0.81) | TLR7 | |
| SCHEMBL14671199 | 0.85 | TLR7 (0.74) | TLR7 | |
| SCHEMBL2568379 | 0.84 | TLR7 (1.00) | TLR7 | |
| SCHEMBL14667669 | 0.82 | TLR7 (0.70) | TLR7 | |
| SCHEMBL2572120 | 0.81 | TLR7 (0.69) | TLR7 | |
| SCHEMBL2568652 | 0.81 | TLR7 (1.00) | TLR7 | |
| SCHEMBL2573488 | 0.81 | TLR7 (0.73) | TLR7 | |
| SCHEMBL255113 | 0.79 | TLR7 (0.63) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC | 2023-10-05 | — | — | US | claimed |
| WO-2022047279-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC (US) | 2022-03-03 | — | — | WO | claimed |
| EP-1987030-B1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | PFIZER LTD (GB) | 2011-11-09 | — | — | EP | claimed |
| US-7691877-B2 | Pharmaceuticals | PFIZER INC. (US) | 2010-04-06 | — | — | US | claimed |
| US-20100029667-A1 | Spray dried formulation | BEND RESEARCH INC. | 2010-02-04 | — | — | US | claimed |
| EP-2101741-A2 | SOLID DISPERSION COMPRISING A POORLY WATER SOLUBLE DRUG | BEND RESEARCH, INC. (US) | 2009-09-23 | — | — | EP | claimed |
| EP-1987030-A1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | Pfizer Limited (GB) | 2008-11-05 | — | — | EP | claimed |
| WO-2008047201-A2 | SOLID DISPERSION COMPRISING A POORLY WATER SOLUBLE DRUG | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | claimed |
| WO-2007093901-A1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | PFIZER LIMITED (GB) | 2007-08-23 | — | — | WO | claimed |
| US-20070197478-A1 | NOVEL PHARMACEUTICALS | PFIZER LIMITED | 2007-08-23 | — | — | US | claimed |
| EP-3568162-B1 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | NEKTAR THERAPEUTICS (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3603619-B1 | VACCINE ADJUVANT FORMULATION | SUMITOMO PHARMA CO LTD (JP) | 2025-08-13 | — | — | EP | disclosed |
| US-12226480-B2 | Combination drug including TLR7 agonist | Sumitomo Pharma Co., Ltd. (JP) | 2025-02-18 | — | — | US | disclosed |
| US-12214045-B2 | Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods | NEKTAR THERAPEUTICS (US) | 2025-02-04 | — | — | US | disclosed |
| US-20250009869-A1 | COMPOSITION CONTAINING INFLUENZA VACCINE | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NAT INSTITUTE OF INFECTIOUS DISEASES (JP) | 2025-01-09 | — | — | US | disclosed |
| WO-2007093901-A1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | PFIZER LIMITED (GB) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093901-A1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | PFIZER LIMITED (GB) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197478-A1 | NOVEL PHARMACEUTICALS | PFIZER LIMITED | 2007-08-23 | — | — | US | disclosed |
| US-20070197478-A1 | NOVEL PHARMACEUTICALS | PFIZER LIMITED | 2007-08-23 | — | — | US | disclosed |
| US-20070197478-A1 | NOVEL PHARMACEUTICALS | PFIZER LIMITED | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12226480-B2 | Combination drug including TLR7 agonist | TLR7, TLR9, CD274 | TLR7 1/4885 |
| US-12214045-B2 | Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods | TLR7, TLR8, TLR3 | TLR7 1/4885 |
| US-20070197478-A1 | NOVEL PHARMACEUTICALS | TLR3, HAVCR2, TLR9 | TLR7 7/4885 |
| US-20100029667-A1 | Spray dried formulation | PRKG1, PDE7A, PDE10A | TLR7 2925/4885 |
| US-20250009869-A1 | COMPOSITION CONTAINING INFLUENZA VACCINE | LY96, CD209, PLA2G12B | TLR7 15/4885 |
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | TLR3, TLR7, TLR8 | TLR7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.